Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 04/28/2025 at 14:15, 1 year 3 months ago

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health to host investor webcast on crofelemer's impact on MVID and SBS-IF patient experience, with results of investigator-initiated trial by Dr. Miqdady presented at ELITE PED-GI Congress in Abu Dhabi

Crofelemer Investor Webcast Jaguar Health MVID SBS-IF
BRIEF

published on 04/17/2025 at 15:05, 1 year 3 months ago

Crofelemer de Jaguar Health : de nouvelles données pour le traitement des maladies rares

Crofelemer Désignation De Médicament Orphelin Maladies Rares Traitement MVID Thérapie SBS-IF
BRIEF

published on 04/17/2025 at 15:05, 1 year 3 months ago

Jaguar Health's Crofelemer: New Data for Rare Disease Treatment

Crofelemer Orphan Drug Designation Rare Diseases MVID Treatment SBS-IF Therapy
PRESS RELEASE

published on 04/17/2025 at 15:00, 1 year 3 months ago

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a plant-based prescription drug, granted Orphan Drug Designation by FDA & EMA for treating rare pediatric diseases, including short bowel syndrome (SBS) & microvillus inclusion disease (MVID). Study presented at ELITE PED-GI Congress

Crofelemer Orphan Drug Designation MVID SBS ELITE PED-GI Congress
BRIEF

published on 04/15/2025 at 15:35, 1 year 3 months ago

Résultats prometteurs de Jaguar Health pour les patientes atteintes d'un cancer du sein lors de la réunion annuelle du MASCC

Crofelemer Jaguar Health Cancer Du Sein Soins De Soutien Discussions De La FDA
BRIEF

published on 04/15/2025 at 15:35, 1 year 3 months ago

Jaguar Health's Promising Results for Breast Cancer Patients at MASCC Annual Meeting

Crofelemer Jaguar Health Breast Cancer Supportive Care FDA Discussions
PRESS RELEASE

published on 04/15/2025 at 15:30, 1 year 3 months ago

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Jaguar Health's crofelemer shows significant results in breast cancer patients for prophylaxis of diarrhea. Late-breaker abstracts on responder analysis and oral mucositis survey results accepted for MASCC's 2025 Annual Meeting

Crofelemer Jaguar Health Breast Cancer Diarrhea Prophylaxis MASCC
BRIEF

published on 04/08/2025 at 14:35, 1 year 4 months ago

Jaguar Health présente Gelclair au congrès de l'Oncology Nursing Society

Jaguar Health Soins Contre Le Cancer Gelclair Mucite Buccale Société Des Soins Infirmiers En Oncologie
BRIEF

published on 04/08/2025 at 14:35, 1 year 4 months ago

Jaguar Health Showcases Gelclair at Oncology Nursing Society Congress

Cancer Care Jaguar Health Gelclair Oral Mucositis Oncology Nursing Society
PRESS RELEASE

published on 04/08/2025 at 14:30, 1 year 4 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Jaguar Health, Inc. (NASDAQ:JAGX) announces Napo Pharmaceuticals' participation in the 50th Oncology Nursing Society Congress to showcase Gelclair® for oral mucositis relief in cancer patients

Napo Pharmaceuticals Cancer Care Jaguar Health Gelclair Oral Mucositis

Published on 08/13/2026 at 14:31, 2 hours 29 minutes ago

Wi2Wi Announces Strategic Equipment Investments to Expand Production Capacity
Published on 08/13/2026 at 14:15, 2 hours 45 minutes ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
Published on 08/13/2026 at 14:00, 3 hours ago

AEONIAN Expands Koocanusa Copper Project to Approximately 412 Km(2); Fieldwork Underway Across Four New Target Areas
Published on 08/13/2026 at 14:00, 3 hours ago

Adcore Reports Q2 2026 Results: Gross Margin Expands to 51% as Revenue Grows 10% to CAD$7.2 million and North America Rebounds 27% to CAD$1.5 million
Published on 08/13/2026 at 14:00, 3 hours ago

GameSquare Appoints Tom Wild as Vice President of Creative Strategy for EMEA

View all ACCESSWIRE

Published on 08/13/2026 at 15:52, 1 hour 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/13/2026 at 15:51, 1 hour 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DNO ASA
Published on 08/13/2026 at 15:51, 1 hour 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 08/13/2026 at 15:50, 1 hour 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 08/13/2026 at 15:49, 1 hour 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 08/11/2026 at 17:45, 1 day 23 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 23 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 23 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 23 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 days 23 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News